CoChat

Adeno-Associated Virus (AAV) - Based Gene Therapies for Retinal Diseases: Where are We?

Open access
Ail, Divya, Malki, Hugo, Zin, Emilia A, Dalkara, Deniz · 2023 · The Application of Clinical Genetics

The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.

Abstract

Owing to their small size and safety profiles, adeno-associated viruses (AAVs) have become the vector of choice for gene therapy applications in the retina. In addition to the naturally occurring AAVs, several engineered variants with enhanced properties are being developed for experimental and therapeutic applications. Nonetheless, there are still some challenges impeding successful application of AAVs for a broader range of retinal gene therapies. The small size of AAV particles ensures efficient tissue transduction but also limits the packaging capacity to a few kilobases. Further, AAV's ability to cross retinal barriers is still an obstacle to pan-retinal transduction of the outer retina with tolerable doses. Lastly, despite overall safety, there have been recent reports of immune responses to AAVs in the eye. Hence, evaluation and prediction of immune responses to AAVs has come to be considered an integral part of future clinical success. This review focuses on the use of AAV in clinical trials for retinal diseases, and discusses developments of variants and novel strategies to overcome immune responses to AAVs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/tacg.s383453

Cites

140 of 140 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Distribution of (A) Naturally occurring AAVs (blue) and engineered AAVs (Orange) used in 53 clinical trials for retinal diseases; (B) distribution of AAV serotypes being used in clinical trials with the naturally occurring ones (AAV2, AAV4, AAV5 and AAV8) in shades of blue and the engineered variants (AAV2tYF, 4D-R100 and AAV2-7m8) in shades of Orange; (C) distribution of the therapeutic strategy used in clinical trials; (D) distribution of clinical trials using the subretinal delivery route for outer retina or other regions of the retina; (E) distribution of clinical trials by injection route including subretinal (Orange) and intravitreal (blue) injections; (F) distribution of trials using intravitreal delivery routes and targeting the inner, outer or other regions of the retina.
Figure 1 Distribution of (A) Naturally occurring AAVs (blue) and engineered AAVs (Orange) used in 53 clinical trials for retinal diseases; (B) distribution of AAV serotypes being used in clinical trials with the naturally occurring ones (AAV2, AAV4, AAV5 and AAV8) in shades of blue and the engineered variants (AAV2tYF, 4D-R100 and AAV2-7m8) in shades of Orange; (C) distribution of the therapeutic strategy used in clinical trials; (D) distribution of clinical trials using the subretinal delivery route for outer retina or other regions of the retina; (E) distribution of clinical trials by injection route including subretinal (Orange) and intravitreal (blue) injections; (F) distribution of trials using intravitreal delivery routes and targeting the inner, outer or other regions of the retina.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 43

Metadata

Authors
Ail, D., Malki, H., Zin, E. A., & Dalkara, D.
Affiliations
Centre National de la Recherche Scientifique (FR)
Corresponding author
  • Ail, Divya
  • Malki, Hugo
  • Zin, Emilia A
  • Dalkara, Deniz
Venue
The Application of Clinical Genetics
Published
2023-05
Volume
Volume 16
Pages
111-130
ISSN
1178-704X (ISSN-L)
OpenAlex
W4379377001
Cited by
40
References
139
Citations by year
2026: 7 · 2025: 13 · 2024: 17 · 2023: 3
FWCI
1.54
Type
journal article
Language
en
Open access
Locations
  • The Application of Clinical Genetics (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
adeno-associated virus, retinal gene therapy, adeno-associated virus vectors, retinal transduction, outer retina, retinal disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.